NetworkNewsBreaks

MondayOct 31, 2016 3:21 pm

Neovasc, Inc. (NVCN) Presenting at the Transcatheter Cardiovascular Therapeutics Symposium

As announced late last week, Neovasc, Inc. (NASDAQ: NVCN), a specialty medical device company, made multiple presentations today at the annual Transcatheter Cardiovascular Therapeutics (TCT) symposium in Washington, D.C., the world's largest educational meeting specializing in interventional cardiovascular medicine. Dr. Anson Cheung, professor of surgery and director of cardiac transplant at St. Paul’s Hospital in Vancouver, Canada, offered an update on the clinical development of the Tiara™ for the transcatheter treatment of mitral valve disease. Meanwhile, Dr. Gregg Stone highlighted the clinical results of the Neovasc Reducer™ for the treatment of refractory angina. This year’s TCT symposium kicked off on…

Continue Reading

MondayOct 31, 2016 2:40 pm

How Net Element, Inc. (NETE) Turns Innovations into Accomplishments

Net Element’s (NASDAQ: NETE) next-generation point-of-sale systems enable innovative and secure payment options via smartphone. In an increasingly competitive landscape, the company’s payment capabilities continue to transform the user’s online and offline mobile experience for the better. “With its smarter, mobile point of sale systems, Net Element is in a sweet spot for growth, not only in the United States but outside of it as well … It has been more than a decade since Net Element launched, and its contributions now extend beyond the mobile payment and value-added transactional innovations offered by subsidiaries like Aptito and TOT Money to…

Continue Reading

MondayOct 31, 2016 12:04 pm

Catalyst Pharmaceuticals, Inc. (CPRX): FDA OKs Phase 3 Firdapse Study; Shares Higher

Shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) are 11% higher after the biopharmaceutical company announced its agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach of the company’s upcoming phase 3 study evaluating Firdapse® for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). Calling the SPA a “major milestone,” Catalyst CEO Patrick J. McEnany said the company now has a regulatory pathway for Firdapse. Catalyst expects to initiate this trial before the end of this year. To view the full press release, visit: http://nnw.fm/S3sgt About…

Continue Reading

MondayOct 31, 2016 12:02 pm

Hemp, Inc. (HEMP) Shares Pushed Higher by Subsidiary’s LOI with BioRegen Innovations

Hemp, Inc. (OTC: HEMP) is trading 15% higher after its Industrial Hemp Manufacturing, LLC (“IHM”) subsidiary announced its Letter of Intent (LOI) with BioRegen Innovations Cooperative, which is currently seeking to build bio regenerative communities throughout the state of North Carolina. Per the agreement, IHM will purchase the raw hemp that is to be harvested from BioRegen's land in eastern North Carolina, with harvest expected toward the end of 2017. To view the full press release, visit: http://nnw.fm/ZGh9v About Hemp, Inc. Hemp, Inc. (OTC PINK: HEMP) seeks to benefit many constituencies from a "Cultural Creative" perspective, thereby not exploiting or…

Continue Reading

MondayOct 31, 2016 12:00 pm

Airborne Wireless Network (ABWN) Applies for FFA Certification of Broadband Transceiver System; Shares Climb

Airborne Wireless Network (OTCQB: ABWN) is trading 7% higher after the company said it has applied and provided related documentation with the Federal Aviation Administration (FAA) for initial certification of the company’s “first-of-its-kind” civilian air-to-air communication system. "Airborne Wireless Network is making application for a Supplemental Type Certificate (STC) for a broadband transceiver system to be installed in Boeing 757-200 aircraft. This new patented broadband system will provide light weight, low power, low cost, microwave relay stations on equipped aircraft. The new system provides a chain of airborne repeaters providing communications along the entire flight paths. The purpose of the…

Continue Reading

FridayOct 28, 2016 3:27 pm

Liquidmetal Technologies, Inc. (LQMT) Advances with EONTEC Collaboration following Completion of $63.4 Million Equity Raise

Earlier this week, Liquidmetal Technologies, Inc. (OTCQB: LQMT) announced completion of the additional closing pursuant to a securities purchase agreement signed with a Hong Kong company owned by Professor Lugee Li in March of this year. Notably, Professor Li is also the Chairman and majority shareholder of EONTEC, a global manufacturing company headquartered in Hong Kong with manufacturing plants in China. In conjunction with this investment, Professor Li became the Chairman of the Board. In a quote, he expressed his excitement to fully incorporate EONTEC’s capabilities with LQMT’s focus on production of high-performance parts, allowing LQMT to address a broad…

Continue Reading

FridayOct 28, 2016 1:37 pm

eXp World Holdings, Inc.’s (EXPI) Cloud-based Brokerage Gains Recognition, Agent Count Ticks Higher

eXp World Holdings (OTCQB: EXPI) continues to beef-up its real estate brokerage division, notching a 151% increase in its agent count compared to the third quarter of last year. At this rate, eXp Realty, the Agent-Owned Cloud Brokerage®, is paced to hit 2,200 agents by year-end. eXp now has professionals covering 41 states, the District of Columbia and Alberta, Canada, demonstrating growing popularity for its cloud-based, virtual reality workspace. "eXp provides top teams and brokerage owners with the opportunity to expand into new markets without additional capital requirements and an agent experience for their members that is collaborative, interpersonal and…

Continue Reading

FridayOct 28, 2016 1:36 pm

Idera Pharmaceuticals, Inc. (IDRA) Widens Loss in Q3, Shares Lower

Idera Pharmaceuticals (NASDAQ: IDRA) posted a third-quarter net loss of $12.9 million, or $(0.10) per basic and diluted share, compared to a net loss of $11.4 million, or $(0.10) per basic and diluted share, for the same period in 2015. Revenue for the 2016 quarter totaled $0.3 million vs. nominal revenue a year ago. To view the full press release, visit: http://nnw.fm/3FPPy About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug…

Continue Reading

FridayOct 28, 2016 1:34 pm

Wider Q1 Loss, Lower Sales Drag ImmunoGen, Inc. (IMGN) Shares Lower

ImmunoGen (NASDAQ: IMGN) shares are lower after the company posted a quarterly net loss of $44.7 million, or $(0.51) per basic and diluted share, on revenues of $7.7 million vs. a net loss of $33.7 million, or $(0.39) per basic and diluted share, on revenues of $14.9 million the year prior. To view the full press release, visit: http://nnw.fm/Jgg6N About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing…

Continue Reading

FridayOct 28, 2016 1:33 pm

Opexa Therapeutics’ (OPXA) Tcelna Misses Endpoints in MS Study, Shares Plunge

Shares of Opexa Therapeutics (NASDAQ: OPXA) sank 68% in morning trade on news the biopharmaceutical company’s phase 2b Abili-T clinical trial to evaluate the efficacy and safety of Tcelna® (imilecleucel-T) in patients with secondary progressive multiple sclerosis (SPMS) failed to meet primary endpoint of reduction in brain volume change (atrophy), nor did it meet the secondary endpoint of reduction of the rate of sustained disease progression. The drug candidate did show a favorable safety and tolerability profile. To view the full press release, visit: http://nnw.fm/eHA99 About Opexa Therapeutics Opexa Therapeutics is a biopharmaceutical company developing personalized immunotherapies based on ImmPath®,…

Continue Reading